In a late-stage experiment including patients with advanced or recurrent endometrial cancer, Imfinzi and Lynparza from AstraZeneca showed promising outcomes when combined with platinum-based chemotherapy.
ALSO READ: Health minister claims, Alcohol and Cocaine found in Imran’s urine sample
In comparison to standard-of-care chemotherapy, either Imfinzi + Lynparza or Imfinzi alone as maintenance therapy improved progression-free survival (PFS) statistically significantly, according to the British pharmaceutical company.
